HealthCare Global Enterprises (HCG) hospital chain has adopted artificial intelligence (AI) technology SigTuple’s AI100 to automate the manual screening process across its hematopathology labs.
This advancement has made HCG the first hospital chain to equip the hematopathology labs across its network with AI screening solutions for disease management and cancer detection. SigTuple’s AI100 is the premium solution for digital hematopathology. It is the only digital hematopathology solution available in India that is robust and economical enough for wide-scale adoption.
Dr. Ajaikumar, executive chairman of HCG, said that AI-powered digital scanning technology has emerged as a game-changer in cancer care. SigTuple’s top-notch solution has brought remarkable precision to hematopathology diagnostic capabilities of HCG, he added.
Read More: AI Tool Allows Clinicians To Make Personalized Chemotherapy Doses For Cancer Patients
The pioneering AI technology’s automation of critical processes and logistics optimization is a distinct value-add for HCG. The advancement aligns with HCG’s overarching goal of serving patients through enhanced clinical outcomes.
Artificial intelligence-assisted digital scanning technology is the future of pathology. The company informed that SigTuple’s AI100 makes it possible for pathologists to review samples remotely without shipping them to the laboratories, as the digital conversion can occur at the site.
This collaboration is expected to drastically reduce the turnaround time, standardize reporting quality, and increase efficiency. The AI solution will enable pathologists to collaborate seamlessly across the globe, thus ensuring every HCG center gets access to experts across the network within seconds.
